Combination Therapy For CNS Lymphoma

Tech ID: 33640 / UC Case 2023-138-0

TECHNOLOGY DESCRIPTION

There are currently no effective therapies for CNS lymphoma. Although B-cell malignancies express CD19, few therapeutic modalities (including CAR-T cells and bispecific T-cell engager antibodies) have overcome severe CNS neurotoxicity. New research suggests that CD19 expression at BBB may mediate neurotoxicity. Our inventor has shown regression of highly refractory CNS lymphoma with tafasitamab and lenalidomide.

STAGE OF DEVELOPMENT

Phase 2 L-MIND trial in patients with refractory non-Hodgkin lymphoma.

RELATED MATERIALS

▶ Tafasitamab at the blood-brain barrier - 01/23/2023

PATENT STATUS

Patent Pending

CONTACT

Gemma E. Rooney
Gemma.Rooney@ucsf.edu
tel: 415-625-9093

OTHER INFORMATION

KEYWORDS

Refractory CNS Lymphoma, B Cell Malignancy, CD19, Tafasitamab, Lenalidomide

CATEGORIZED AS

▶ Medical
▶ Disease: Cancer
▶ Therapeutics

RELATED CASES

2023-138-0

ADDRESS

UCSF Innovation Ventures
600 16th St, Genentech Hall, S-272,
San Francisco,CA 94158

CONTACT

Tel:
innovation@ucsf.edu
https://innovation.ucsf.edu
Fax:

CONNECT

© 2024, The Regents of the University of California
Terms of use Privacy Notice